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A randomized placebo-controlled phase 3 trial of adjuvanted herpes zoster subunit vaccine has 
shown a substantial improvement in vaccine efficacy in adults aged 70 years and over compared to 
the current live attenuated vaccine. The finding has profound implications for reducing illness 
burden, although the duration of vaccine protection needs further evaluation. 
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Herpes zoster causes major morbidity among older people. The incidence of the disease rises 
dramatically with age, with a lifetime zoster risk for those aged ≥85 years approaching 50%1. 
Moreover, the risk of post-herpetic neuralgia — a debilitating neuropathic pain syndrome — 
increases markedly after the age of 50 years2. Case fatality of herpes zoster is also highly age-
correlated: more than 95% of deaths occur in people aged ≥60 years3. T-cell mediated immunity, 
which controls reactivation of the varicella zoster virus (VZV) from latency and promotes recovery 
after herpes zoster, declines progressively with age4. In addition, cell-mediated immune response to 
the currently licensed live attenuated zoster vaccine is lower in older age groups, and the effects of 
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the vaccine wane over time4. Identification of more-effective strategies to prevent zoster among 
older adults is, therefore, essential. 
In a GlaxoSmithKline-funded study, published recently in the New England Journal of Medicine, 
Anthony Cunningham and colleagues reported impressive efficacy of an adjuvanted herpes zoster 
subunit vaccine in adults aged 70 years and over5. 
 
In the study, known as ZOE-70, 13,900 participants with a mean age of 75.6 years were recruited 
from 18 countries and randomly allocated to receive either two doses of an investigational herpes 
zoster subunit vaccine (HZ/su; GSK vaccines) or placebo5. The new vaccine contained 50 µg of 
recombinant VZV glycoprotein E and the liposome-based AS01b adjuvant system, which enhances 
CD4+ T-cell and humoral immune responses to recombinant proteins. Over 3.7 years of follow up, 
only 23 confirmed cases of herpes zoster were observed in the vaccinated group, whereas 223 cases 
were confirmed in the placebo group, meaning that the vaccine efficacy (VE) for preventing herpes 
zoster in individuals who had received both vaccine doses was 89.8% (95% CI 84.2- 93.7).  
 
To increase statistical power of the study, authors conducted several prespecified pooled analyses 
between participants from ZOE-70 and the ZOE-50 trial. The ZOE-50 trial was conducted by the same 
group of investigators, and used methods identical to ZOE-70 to investigate efficacy of HZ/su vaccine 
in adults aged ≥50 years6. The results of the ZOE-50 trial were published last year and showed a very 
marked reduction in herpes zoster among vaccinated participants in this age-group (VE 97.2% (95% 
C.I. 93.7- 99.0)). Combined analysis of all 16,596 ZOE-50 and ZOE-70 trial participants aged ≥70 years 
showed a 91.3% (95% CI 86.8-94.5%) VE against herpes zoster. In another prespecified pooled 
analysis of ZOE-50 and ZOE-70 trial participants aged ≥50 years, VE against post-herpetic neuralgia 
was 88.8% (95% CI 68.7-97.1%). 
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The choice of primary end point in the present study — reduction in herpes zoster incidence — is 
supported by a recent review of endpoints in zoster vaccine studies7, which concluded that use of 
the main alternative endpoint, burden of illness (determined by averaging pain severity and duration 
scores based on the Zoster Brief Pain Inventory), tends to overestimate VE7. Although other studies 
have considered the effect of zoster vaccine on activities of daily living or health-related quality of 
life, the main effect of zoster vaccine on these endpoints is through preventing zoster, rather than by 
attenuating severity or duration of illness7, which supports the approach Cunningham and co-
investigators took. 
 
The results of ZOE-70 are noteworthy for several reasons: first, they demonstrate a marked increase 
in efficacy over the current vaccine, which is licensed for adults aged 50 years and over. This is a live 
attenuated Oka/Merck VZV vaccine (Zostavax), shown in the landmark Shingles Prevention Study to 
reduce herpes zoster incidence by 51.1%, burden of illness attributed to shingles by 61.1%, and post 
herpetic neuralgia by 66.5%8. Second, efficacy of the new subunit vaccine did not diminish with 
advancing age: VE was 90.0% in those aged 70-79 years and 89.1% in participants aged 80 years or 
older. This compares favourably to age-stratified VE estimates for the current live attenuated 
vaccine of 69.8% in participants aged 50 to 59 years9, 63.9% among subjects aged 60-69 years and 
37.6% among those aged 70 years and over8 for reducing herpes zoster incidence. 
  
Establishing an adequate immune response to vaccines in older people is challenging: in general, the 
size, duration and quality of response, regardless of vaccine type, is lower than in younger people4. 
The high efficacy of the new HZ/su vaccine suggests that the vaccine is able to overcome some of the 
processes associated with senescence of adaptive immunity, notably the high background 
inflammatory state implicated in age-related alterations to T-cell immunity10, which can inhibit T-cell 
activation following vaccination in older people. Better understanding of the biology underlying the 
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findings from ZOE-70 could, therefore, have more general implications for improving vaccine efficacy 
in the elderly  
  
Besides older people, the HZ/su vaccine could benefit other groups with impaired cell-mediated 
immunity— such as those individuals on immunosuppressive therapies or with various 
haematological malignancies — who may be at high risk of herpes zoster but in whom live vaccine is 
contraindicated. HZ/su vaccine is not a live vaccine and as such, the virus cannot replicate. The 
vaccine can, therefore, theoretically be used in immunocompromised people, although this was not 
tested in the trial, and safety and efficacy in this group would require further investigation. 
 
One potential disadvantage of the HZ/su vaccine is the higher frequency of solicited injection-site 
and systemic reactions, most frequently fatigue, reported within 7 days of the vaccine compared 
with placebo (79.0% versus 29.5%). These adverse reactions tended to be transient, mild to 
moderate reactions, with a median duration of 2-3 days for injection site reactions and 1-2 days for 
systemic reactions. Systemic reactions were more frequently reported in HZ/su vaccine recipients 
(53.0%)5 than in recipients of live attenuated vaccine (25%)8. Importantly, rates of serious adverse 
events, immune-mediated disease and deaths did not differ between HZ/su vaccine and placebo 
groups. Another potential issue is compliance: the subunit vaccine requires two doses given 2 
months apart, rather than one dose as is the case for live attenuated vaccine. Encouragingly, VE 
results for the total vaccinated cohort (including people who received only one vaccine) remained 
high, with VE of 87.7% (95% CI 82.0-92.0%). 
 
The duration of protection provided by the HZ/su vaccine remains an open question. Efficacy of the 
live attenuated vaccine declines markedly over the post-vaccination years 3 to 11. Although waning 
of HZ/su vaccine-induced immunity will start from a higher baseline, accurate assessment of the 
likely duration of protection is of key importance to inform cost-effectiveness estimates and, 
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ultimately, the design of effective public health programmes. The HZ/su vaccine offers the exciting 
prospect of seriously reducing the population burden of zoster complications, especially in settings 
that already achieve a relatively high vaccine uptake. 
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